Business Description
Abliva AB
ISIN : SE0002575340
Compare
Compare
Traded in other countries / regions
ABLI.Sweden0QDU.UKNTP.GermanyNEVPF.USA IPO Date
2014-02-21Description
Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase. . The company is focused on two projects. KL1333, a powerful NAD+ and NADH regulator, in late-stage development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement therapy, has just completed preclinical development.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 209.51 | |||||
| Equity-to-Asset | 0.89 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -5.45 | |||||
| Beneish M-Score | -3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 29.1 | |||||
| 3-Year EPS without NRI Growth Rate | 27.4 | |||||
| 3-Year FCF Growth Rate | 67.8 | |||||
| 3-Year Book Growth Rate | -38.8 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.31 | |||||
| Quick Ratio | 6.31 | |||||
| Cash Ratio | 5.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -51.5 | |||||
| Shareholder Yield % | -18.57 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -76128.47 | |||||
| Net Margin % | -74541.61 | |||||
| FCF Margin % | -42692.31 | |||||
| ROE % | -123 | |||||
| ROA % | -106.96 | |||||
| ROIC % | -247.34 | |||||
| ROC (Joel Greenblatt) % | -13063.09 | |||||
| ROCE % | -122.32 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.66 | |||||
| EV-to-EBIT | -1.66 | |||||
| EV-to-Forward-EBIT | -0.7 | |||||
| EV-to-EBITDA | -1.84 | |||||
| EV-to-Forward-EBITDA | -0.71 | |||||
| EV-to-Revenue | 1236.86 | |||||
| EV-to-Forward-Revenue | 634.02 | |||||
| EV-to-FCF | -2.91 | |||||
| Earnings Yield (Greenblatt) % | -60.24 | |||||
| FCF Yield % | -27.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:NEVPF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Abliva AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.013 | ||
| EPS (TTM) ($) | -0.009 | ||
| Beta | 9510.93 | ||
| Volatility % | 115.8 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0.000007 | ||
| 20-Day SMA ($) | 0.01 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 0.01 - 0.02 | ||
| Shares Outstanding (Mil) | 1,611.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Abliva AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Abliva AB Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Abliva AB Frequently Asked Questions
What is Abliva AB(NEVPF)'s stock price today?
The current price of NEVPF is $0.01. The 52 week high of NEVPF is $0.02 and 52 week low is $0.01.
When is next earnings date of Abliva AB(NEVPF)?
The next earnings date of Abliva AB(NEVPF) is 2025-02-21.
Does Abliva AB(NEVPF) pay dividends? If so, how much?
Abliva AB(NEVPF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers